Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1I0LQ
|
|||
| Drug Name |
Nemvaleukin alfa
|
|||
| Drug Type |
Fusion protein
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 3 | [1] | |
| Cutaneous melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [2] | ||
| Company |
Alkermes Waltham, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | IL-1 receptor-like 2 (IL1RL2) | Target Info | Agonist | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05092360) A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04830124) A Phase 2, Open Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6. U.S.National Institutes of Health. | |||
| REF 3 | Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. J Immunother Cancer. 2022 Sep;10(9):e004913. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.